Back to Journals » Drug Design, Development and Therapy » Volume 12

Effect of butorphanol on opioid-induced cough: a meta-analysis of randomized controlled trials

Authors Zhang J, Miao S, Tu Q, Shi M, Zou L, Liu S, Wang G

Received 17 July 2018

Accepted for publication 27 August 2018

Published 2 October 2018 Volume 2018:12 Pages 3263—3268


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Anastasios Lymperopoulos

Jian Zhang,1,* Shuai Miao,2,* Qing Tu,3 Mengzhu Shi,2 Lan Zou,2 Su Liu,2 Guanglei Wang2

1Department of Anesthesiology, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, China; 2Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; 3Department of Anesthesiology, Tangshan People’s Hospital, North China University of Science and Technology, Tangshan, Hebei, China

*These authors contributed equally to this study

Objective: The aim of this study was to assess the effect of butorphanol on the prevention of opioid-induced cough by a meta-analysis.
Materials and methods: We searched PubMed, Embase, The Cochrane Library, and the China National Knowledge Infrastructure database for relevant randomized controlled trials (RCTs) to demonstrate the efficacy of butorphanol on the prevention of opioid-induced cough. We used RevMan 5.3 to conduct a meta-analysis on each outcome.
Results: Eight RCTs comparing 942 patients were included in this study. The pooled meta-analysis showed that the incidence of opioid-induced cough in the butorphanol group was significantly decreased compared with that of the control group (risk ratio [RR]=0.17, 95% CI [0.09, 0.33], P<0.00001). Incidences of opioid-induced cough in the butorphanol group resulting in mild cough (RR=0.30, 95% CI [0.11, 0.78], P=0.01), moderate cough (RR=0.08, 95% CI [0.03, 0.22], P<0.00001), or severe cough (RR=0.08, 95% CI [0.02, 0.30], P=0.0001) were significantly lower than those of the control group.
Conclusion: This meta-analysis suggested that butorphanol can effectively prevent the incidence of opioid-induced cough and reduce the severity of opioid-induced cough.

Keywords: butorphanol, opioid, cough, meta-analysis, randomized controlled trial

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]